Veterinary Excipients Market Size & Growth Forecast 2026–2035, By Segments (Animal Type, Application, Chemical Group, Function), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Base Year Value (2025)
USD 1.21 Billion
CAGR (2026-2035)
4.3%
Forecast Year Value (2035)
USD 1.84 Billion
Historical Data Period
2022-2025
Largest Region
North America
Forecast Period
2026-2035
Veterinary Excipients Market Intelligence Snapshot:
-
Regional Market Dynamics:
- North America leads due to a mature animal health pharmaceutical base, strong formulation capabilities, and consistent demand for excipients improving stability, delivery, and dosing performance.
- Asia Pacific is expanding at 4.9% CAGR, driven by rising veterinary pharmaceutical production, growing companion and livestock care demand, and increasing adoption of advanced formulation systems.
-
Segment Momentum:
- Production Animals held a 59.85% share in 2025 due to large-scale livestock treatment programs that rely on excipients for dosage consistency, formulation stability, and efficient administration across high-volume operations.
- Biologics are growing fastest because they require specialized excipients to preserve activity, enhance stability, and meet the stricter formulation needs of increasingly advanced veterinary therapies.
-
Market Expansion Drivers:
- Rising global pet healthcare expenditure increasing demand for high-quality veterinary pharmaceutical excipients.
- Expanding international regulatory harmonization driving compliance-focused excipient manufacturing investments.
- Growing outsourcing to veterinary CDMOs accelerating specialized excipient production capabilities.
-
Leading Market Participants:
Major companies in the veterinary excipients market include Croda International Plc (United Kingdom), BASF SE (Germany), Ashland Inc. (USA), JRS Pharma GmbH & Co. KG (Germany), Colorcon Inc. (USA), IOI Oleo GmbH (Germany), Lipoid GmbH (Germany), Gattefossé SAS (France), Azelis Group NV (Belgium), Spectrum Chemical Manufacturing Corp. (USA).
Global Market Forecast Snapshot:
-
Market Outlook:
- 2025 Market Size: USD 1.21 Billion
- Projected Market Size: USD 1.84 Billion by 2035
- Growth Forecasts: 4.3% CAGR (2026-2035)
-
Regional and Segment Outlook:
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Production Animals (Animal Type) | Pharmaceuticals (Application) | Polymers (Chemical Group) | Solubilizers/ Solvents (Function)
- Emerging Opportunity Segment: Companion Animals (Animal Type) | Biologics (Application) | Lipids (Chemical Group) | Solubilizers/ Solvents (Function)
Market Growth Drivers and Industry Trends
Rising global pet healthcare expenditure increasing demand for high-quality veterinary pharmaceutical excipientsAs pet owners allocate more spending to diagnostics, chronic disease treatment, preventive care, and advanced therapeutics, animal health companies are under greater pressure to deliver veterinary medicines with stronger palatability, stability, dose consistency, and ease of administration. That shift directly supports demand in the veterinary excipients market because excipients play a central role in improving formulation performance for chewables, liquids, injectables, and species-specific dosage forms. Manufacturers responding to premiumization in companion animal care tend to favor higher-grade excipient systems that can help differentiate products through shelf life, bioavailability support, and administration convenience, reinforcing market demand as veterinary drug portfolios become more sophisticated.
Expanding international regulatory harmonization driving compliance-focused excipient manufacturing investments
As regulatory expectations for veterinary medicines become more aligned across jurisdictions, excipient suppliers face a stronger commercial incentive to build manufacturing and documentation systems that can satisfy multiple markets with fewer formulation changes. In the veterinary excipients market, this is pushing investment toward tighter quality control, traceability, validated processes, and standardized technical dossiers, since animal health manufacturers increasingly prefer suppliers that reduce approval complexity and compliance risk. The practical effect is a gradual shift in purchasing toward excipient producers able to support cross-border product registration and consistent quality assurance, driving market development around compliant, audit-ready supply capabilities.
Growing outsourcing to veterinary CDMOs accelerating specialized excipient production capabilities
The expansion of outsourced development and manufacturing in animal health is changing how formulation expertise is sourced, with veterinary CDMOs taking on a larger role in designing species-appropriate dosage forms and scalable production processes. This is influencing the veterinary excipients market by concentrating demand among technically advanced buyers that require excipients tailored for specific delivery formats, processing conditions, and animal acceptability profiles. As CDMOs broaden their formulation services, excipient suppliers are pushed to develop more specialized grades, application support, and smaller-batch flexibility, contributing to market size growth through closer alignment between outsourced drug development needs and excipient innovation.
| Growth Driver Assessment Framework | |||||
| Growth Driver | Impact On CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising global pet healthcare expenditure increasing demand for high-quality veterinary pharmaceutical excipients | 2.00% | Moderate | North America, Europe | High | Near Term |
| Expanding international regulatory harmonization driving compliance-focused excipient manufacturing investments | 1.60% | High | Europe, North America, Asia Pacific | Medium | Mid Term |
| Growing outsourcing to veterinary CDMOs accelerating specialized excipient production capabilities | 1.30% | Moderate | Asia Pacific, Europe | Emerging | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions - Click to get your customized report now!
Regional Demand Dynamics
Largest Region
North America
XX% Market Share in 2025
North America held the largest regional market share in 2025 for the veterinary excipients market, supported by the region’s well-established animal health industry and mature pharmaceutical manufacturing base. Its leadership is aided by consistent demand for formulated veterinary products, where excipients play a practical role in improving stability, delivery, palatability, and dosage performance across companion animal and livestock medicines. The region’s market activity is supported by established production capabilities, strong commercialization pipelines, and routine use of specialized formulation inputs in regulated product development.
Asia Pacific is projected to expand at a 4.9% CAGR over the forecast period, with the veterinary excipients market gaining momentum as animal health production and pharmaceutical formulation activity continue to broaden across the region. Growth is being impelled by rising development of veterinary medicines and increasing use of more advanced formulation approaches that require reliable excipient systems for product effectiveness and manufacturability. As local production scales and veterinary care demand deepens across both farm and companion animal segments, adoption is accelerating in ways that directly lift excipient consumption.
Key Country Insights
The U.S. emphasizes advanced veterinary excipients that improve formulation stability, palatability, and controlled drug delivery across companion and livestock animal medicines. Manufacturers increasingly collaborate with animal health companies to develop excipients suited for diverse dosage forms and evolving veterinary treatment requirements.
Japan focuses on veterinary excipients designed for companion animal pharmaceuticals, where ease of administration and formulation precision remain important. Companies in Japan increasingly refine excipient technologies that improve dosage consistency and support specialized veterinary therapies.
South Korea strengthens its veterinary excipients market through investments in pharmaceutical manufacturing capabilities and modern formulation technologies. Producers in South Korea increasingly develop multifunctional excipients that improve processing efficiency while supporting a broader portfolio of veterinary medicines.
Germany prioritizes high-performance veterinary excipients that support consistent manufacturing quality and regulatory compliance. Suppliers in Germany concentrate on reliable functional ingredients that enhance product stability while meeting the needs of pharmaceutical manufacturers serving multiple animal health segments.
France emphasizes veterinary excipients that support reliable formulations for livestock healthcare and preventive treatment programs. Manufacturers serving France prioritize excipient performance that enhances product stability while addressing practical requirements across commercial animal production systems.
Italy focuses on veterinary excipients that enable versatile dosage formulations for both companion and farm animals. Pharmaceutical companies in Italy increasingly seek excipient solutions that simplify product development while maintaining formulation quality across diverse veterinary applications.
Segment Leadership and Growth Trends
Production Animals held the leading position in the veterinary excipients market in 2025, accounting for a 59.85% share. This leadership is underpinned by the steady and large-scale use of veterinary formulations across livestock populations, where excipients are required to support dosage consistency, stability, and administration across high-volume treatment programs. The production-focused side of the veterinary excipients market benefits from routine and operationally driven demand, as animal health management in farm settings depends on dependable pharmaceutical inputs used at scale.
Companion Animals are emerging as the fastest-growing segment in the veterinary excipients market as treatment expectations continue to shift toward more specialized and consumer-sensitive animal care. Growth is being supported by rising demand for formulations that improve palatability, delivery convenience, and product differentiation for pets, which creates stronger need for tailored excipient systems than in conventional volume-driven applications. Compared with production animals, this segment is gaining momentum from evolving care patterns and the expanding use of advanced veterinary products in companion animal treatment.
Application Segment Analysis: Pharmaceuticals (Largest Segment) vs Biologics (Fastest-Growing Segment)
In 2025, Pharmaceuticals represented the largest application in the veterinary excipients market with a 58.8% share. Its leading position reflects the broad and established use of excipients in conventional veterinary drug formulations, where they play a practical role in ensuring product stability, manufacturability, and controlled delivery. The pharmaceuticals segment remains dominant because it is tied to routine formulation needs across a wide range of veterinary treatments, making excipient demand more consistently embedded in standard product development and production.
Biologics are the fastest-growing application in the veterinary excipients market, encouraged by the rising need for formulation support in more sensitive and complex therapeutic products. This segment is seeing wider adoption because biologic products typically require excipients that can preserve activity, improve stability, and support handling requirements that are more demanding than those of traditional pharmaceutical formulations. Relative to conventional applications, biologics are expanding faster as product development increasingly moves toward advanced veterinary therapies with stricter formulation requirements.
| Report Segmentation | |||
| Segment | Sub-Segment | Largest Segment | Fastest Growing Segment |
|---|---|---|---|
| Animal Type | Production Animals, Companion Animals | Production Animals | Companion Animals |
| Application | Biologics, Pharmaceuticals, Medicated Feed Additives | Pharmaceuticals | Biologics |
| Chemical Group | Polymers, Alcohols, Lipids, Mineral Salts, Others | Polymers | Lipids |
| Function | Solubilizers/ Solvents, Binders, Stabilizers, Coating, Diluents & Fillers , Others | Solubilizers/ Solvents | Solubilizers/ Solvents |
Read our Research ApproachCompetitive Landscape and Market Positioning
Top players in the veterinary excipients market:1. Croda International Plc (United Kingdom)
2. BASF SE (Germany)
3. Ashland Inc. (USA)
4. JRS Pharma GmbH & Co. KG (Germany)
5. Colorcon Inc. (USA)
6. IOI Oleo GmbH (Germany)
7. Lipoid GmbH (Germany)
8. Gattefossé SAS (France)
9. Azelis Group NV (Belgium)
10. Spectrum Chemical Manufacturing Corp. (USA)
The veterinary excipients market is evolving through increased demand for specialized animal healthcare formulations and improved drug delivery performance. Manufacturers are focusing on advanced excipient technologies that enhance stability, palatability, and bioavailability across veterinary medicines. Expansion into companion animal healthcare and livestock treatment applications is also supporting broader market development.
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Clariant | Aug-23 | Clariant launched three specialized VitiPure excipients—VitiPure O 80 Superior, VitiPure Meglumine LEX, and VitiPure CO 35—at CPHI Barcelona. These high-purity solubilizers and emulsifiers are engineered for both human and veterinary pharmaceutical applications, supporting the company's strategic focus on supplying advanced ingredients for modern biologics and specialized drug formulations. |
| TheraVet | May-22 | TheraVet entered an exclusive distribution partnership with Nuzoa to launch the BIOCERA-VET product line in Spain. This collaboration leverages Nuzoa’s established veterinary distribution network to accelerate market penetration and commercial accessibility for TheraVet’s specialized veterinary orthopedic solutions. |
| Seppic | Nov-21 | Seppic introduced MONTANIDE GEL P PR, an aqueous adjuvant specifically developed for injectable avian vaccines. This technology-led product innovation expands the company's veterinary portfolio, providing manufacturers with enhanced tools to improve the efficacy and stability of poultry immunization programs. |
| Colorcon | Jul-19 | Colorcon announced plans to construct a new starch manufacturing facility in the Netherlands. This capital expenditure was initiated to scale global production capacity for pharmaceutical excipients, ensuring supply chain resilience and meeting the sustained demand for high-quality functional ingredients across the global pharmaceutical and veterinary sectors. |
Why Choose Us
Specialized Expertise: Our team comprises industry experts with a deep understanding of your market segment. We bring specialized knowledge and experience that ensures our research and consulting services are tailored to your unique needs.
Customized Solutions: We understand that every client is different. That's why we offer customized research and consulting solutions designed specifically to address your challenges and capitalize on opportunities within your industry.
Proven Results: With a track record of successful projects and satisfied clients, we have demonstrated our ability to deliver tangible results. Our case studies and testimonials speak to our effectiveness in helping clients achieve their goals.
Cutting-Edge Methodologies: We leverage the latest methodologies and technologies to gather insights and drive informed decision-making. Our innovative approach ensures that you stay ahead of the curve and gain a competitive edge in your market.
Client-Centric Approach: Your satisfaction is our top priority. We prioritize open communication, responsiveness, and transparency to ensure that we not only meet but exceed your expectations at every stage of the engagement.
Continuous Innovation: We are committed to continuous improvement and staying at the forefront of our industry. Through ongoing learning, professional development, and investment in new technologies, we ensure that our services are always evolving to meet your evolving needs.
Value for Money: Our competitive pricing and flexible engagement models ensure that you get maximum value for your investment. We are committed to delivering high-quality results that help you achieve a strong return on your investment.
Select Licence Type
